NCT05500391 2026-03-18
SUR-CAN
Centre Oscar Lambret
Phase 2 Recruiting
Clinical Trials
17 trialsNCT05551117 2026-02-09
Tamarack
MacroGenics
Phase 2 Terminated
NCT03333616 2026-01-21
Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT04926181 2025-05-15
Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer
University of California, San Francisco
Phase 2 Terminated
NCT02489903 2025-03-17
RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
EpicentRx, Inc.
Phase 2 Completed
NCT02608411 2023-10-13
TIMES
Istituto Oncologico Veneto IRCCS
Phase 2 Terminated
NCT01470248 2021-02-17
Study of Arsenic Trioxide in Small Cell Lung Cancer
Emory University
Phase 2 Completed
NCT00298896 2018-07-26
Safety and Efficacy Clinical Study of SNS-595 in Patients With Advanced Small Cell Lung Cancer
Sunesis Pharmaceuticals
Phase 2 Completed
NCT00129974 2017-06-16
Study of Pemetrexed and Gemcitabine for Patients With a New Diagnosis of Extensive-Stage Small Cell Lung Cancer
Tufts Medical Center
Phase 2 Terminated
NCT00907569 2016-02-22
Hypofractionated Radiotherapy for Limited Stage Small Cell Lung Cancer
AHS Cancer Control Alberta
Phase 2 Completed
NCT00284154 2013-03-13
Vinflunine in the Treatment of Patients With Relapsed Extensive Small Cell Lung Cancer
SCRI Development Innovations, LLC
Phase 2 Completed
NCT00305942 2013-01-31
Topotecan and Carboplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer
SCRI Development Innovations, LLC
Phase 2 Completed
NCT00294190 2012-12-10
Higher Dose Weekly Topotecan In The Treatment Of Patients With Extensive Stage Small-Cell Lung Cancer
SCRI Development Innovations, LLC
Phase 2 Completed
NCT00324558 2012-06-08
Adjuvant BEmiparin in Small Cell Lung Carcinoma (ABEL STUDY)
Clinica Universidad de Navarra, Universidad de Navarra
Phase 2 Terminated
NCT00046787 2011-10-20
Efficacy and Safety Study of OSI-211 (Liposomal Lurtotecan) to Treat Recurrent Small Cell Lung Cancer
Astellas Pharma Inc
Phase 2 Completed
NCT00906061 2009-05-21
Biweekly Gemcitabine and Docetaxel as First Line Therapy for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients
Hospital Arnau de Vilanova
Phase 2 Unknown
NCT00191750 2007-01-26
A Study of Pemetrexed in Small Cell Lung Cancer, Which Has Returned
Eli Lilly and Company
Phase 2 Completed